About

David E. Taylor is an Associate Professor in the Department of Philosophy at the University of Minnesota and a resident fellow at the Minnesota Center for Philosophy of Science. His primary research focuses on topics at the intersection of metaphysics and the philosophy of language. He also has interests in metaethics and the history of analytic philosophy. Currently, he is working on two related projects: one concerning the phenomenon of indeterminacy, exploring its nature, logic, and various manifestations; and another concerning the relationship between deflationary theories of ontology and deflationary theories of truth.

Research topics

• Internal medicine
• Cardiology
• Medicine
• Pathology
• Acoustics
• Materials science
• Oncology
• Biomedical engineering

Selected publications

• FUNCTIONAL HYPOTHALAMIC AMENORRHEA AND PROINFLAMMATORY CYTOKINES

  Fertility and Sterility · 2023-10-01

  articleOpen access
  PublisherOA PDFDOI

• <scp>MCS</scp>and Novel Adjunctive Therapies: An Update

  2023-09-08

  other1st authorCorresponding

  In the USA, Europe, and Japan, almost three-quarters of a million people die annually from congestive heart failure (HF). This chapter explores the potential for left ventricular assist devices (LVADs) and regenerative medicine strategies alone or together as a potential option for these individuals. With strong clinical and technological development, mechanical circulatory support devices are today widely used in patients with end-stage HF. The chapter discusses the development of cell- and gene-based therapies as potential adjuvant therapies for HF patients implanted with LVADs. In transplant ineligible patients with end-stage HF, LVADs can serve as destination (i.e. last resort) therapy to prolong life. Cell-based therapy and LVAD support theoretically should represent an ideal complementary treatment option for advanced HF. Biorepositories have played a significant role in investigating the effects of cell therapy on myocardium remodeling and cardiac recovery in patients with HF and their response to mechanical unloading.

  PublisherDOI

• Correction to: Analysis of sex-based differences in clinical and molecular responses to ischemia reperfusion after lung transplantation

  Respiratory Research · 2022-09-07

  erratumOpen access
  PublisherOA PDFDOI

• The Nevada Turnaround:

  The New Press eBooks · 2021-09-07

  book-chapter1st authorCorresponding
  PublisherDOI

• Recommendations for nomenclature and definition of cell products intended for human cardiovascular use

  Cardiovascular Research · 2021-08-11 · 8 citations

  articleOpen access1st author

  Exogenous cell-based therapy has emerged as a promising new strategy to facilitate repair of hearts damaged by acute or chronic injury. However, the field of cell-based therapy is handicapped by the lack of standardized definitions and terminology, making comparisons across studies challenging. Even the term 'stem cell therapy' is misleading because only a small percentage of cells derived from adult bone marrow, peripheral blood, or adipose tissue meets the accepted haematopoietic or developmental definition of stem cells. Furthermore, cells (stem or otherwise) are dynamic biological products, meaning that their surface-marker expression, phenotypic and functional characteristics, and the products they secrete in response to their microenvironment can change. It is also important to point out that most surface markers are seldom specific for a cell type. In this article, we discuss the lack of consistency in the descriptive terminology used in cell-based therapies and offer guidelines aimed at standardizing nomenclature and definitions to improve communication among investigators and the general public.

  PublisherOA PDFDOI

• Construction and Evaluation of a Bio-Engineered Pump to Enable Subpulmonary Support of the Fontan Circulation: A Proof-of-Concept Study

  ASAIO Journal · 2021-12-01 · 4 citations

  articleSenior authorCorresponding

  Our objective was to create a bio-engineered pump (BEP) for subpulmonary Fontan circulation support capable of luminal endothelialization and producing a 2-6 mmHg pressure gradient across the device without flow obstruction. To accomplish this, porcine urinary bladder submucosa was decellularized to produce a urinary bladder matrix (UBM) which produced acellular sheets of UBM. The UBM was cultured with human umbilical vein endothelial cells producing a nearly confluent monolayer of cells with the maintenance of typical histologic features demonstrating UBM to be a suitable substrate for endothelial cells. A lamination process created bilayer UBM sheets which were formed into biologic reservoirs. BEPs were constructed by securing the biologic reservoir between inlet and outlet valves and compressed with a polyurethane balloon. BEP function was evaluated in a simple flow loop representative of a modified subpulmonary Fontan circulation. A BEP with a 92-mL biologic reservoir operating at 60 cycles per minute produced pulsatile downstream flows without flow obstruction and generated a favorable pressure gradient across the device, maintaining upstream pressure of 6 mm Hg and producing downstream pressure of 13 mm Hg. The BEP represents potential long-term assistance for the Fontan circulation to relieve venous hypertension, provide pulsatile pulmonary blood flow and maintain cardiac preload.

  PublisherDOI

• Incidence of primary graft dysfunction is higher according to the new ISHLT 2016 guidelines and correlates with clinical and molecular risk factors

  Journal of Thoracic Disease · 2021-06-01 · 12 citations

  articleOpen access

  BACKGROUND: Primary graft dysfunction (PGD) is the most important determinant of morbidity and mortality after lung transplantation, but its definition has evolved over the past decade. The implications of this refinement in clinical definition have not been evaluated. In this single-center study, we compared PGD incidence, risk factors, and outcomes using the 2005 and the updated-2016 International Society of Heart and Lung Transplantation guidelines for PGD grading in lung transplant patients. METHODS: In this retrospective study, we extracted data from the medical records of 127 patients who underwent lung transplantation between 1/1/2016-12/31/2018. PGD was defined as PGD3 present at 48 and/or 72 hours post-reperfusion. We used the 2005 and the updated 2016 guidelines to assess clinical risk factors, outcomes, and baseline biomarkers for PGD. RESULTS: On the basis of the 2016 and 2005 guidelines, we identified PGD in 37% and 26% of patients, respectively. PGD was significantly associated with extracorporeal life support, large body mass index, and restrictive lung disease using the 2016 but not the 2005 guidelines. Based on the 2016 guidelines, pretransplant levels of several biomarkers were associated with PGD; using the 2005 guidelines, only increased interleukin-2 levels were significantly associated with PGD. No preoperative biomarkers were associated with PGD using either guidelines after adjusting for clinical variables. Postoperative morbidity and 1-year mortality were similar regardless of guidelines used. CONCLUSIONS: Our findings suggest that refinements in the PGD scoring system have improved the detection of graft injury and associated risk factors without changing its ability to predict postoperative morbidity and mortality.

  PublisherOA PDFDOI

• Analysis of sex-based differences in clinical and molecular responses to ischemia reperfusion after lung transplantation

  Respiratory Research · 2021-12-22 · 12 citations

  articleOpen access

  BACKGROUND: Sex and hormones influence immune responses to ischemia reperfusion (IR) and could, therefore, cause sex-related differences in lung transplantation (LTx) outcomes. We compared men's and women's clinical and molecular responses to post-LTx IR. METHODS: In 203 LTx patients, we used the 2016 International Society for Heart and Lung Transplantation guidelines to score primary graft dysfunction (PGD). In a subgroup of 40 patients with blood samples collected before LTx (T0) and 6, 24, 48 (T48), and 72 h (T72) after lung reperfusion, molecular response to IR was examined through serial analysis of circulating cytokine expression. RESULTS: After adjustment, women had less grade 3 PGD than men at T48, but not at T72. PGD grade decreased from T0 to T72 more often in women than men. The evolution of PGD (the difference in mean PGD between T72 and T0) was greater in men. However, the evolution of IL-2, IL-7, IL-17a, and basic fibroblast growth factor levels was more often sustained throughout the 72 h in women. In the full cohort, we noted no sex differences in secondary clinical outcomes, but women had significantly lower peak lactate levels than men across the 72 h. CONCLUSIONS: Men and women differ in the evolution of PGD and cytokine secretion after LTx: Women have a more sustained proinflammatory response than men despite a greater reduction in PGD over time. This interaction between cytokine and PGD responses warrants investigation. Additionally, there may be important sex-related differences that could be used to tailor treatment during or after transplantation.

  PublisherOA PDFDOI

• Peripheral Blood Biomarkers Associated With Improved Functional Outcome in Patients With Chronic Left Ventricular Dysfunction: A Biorepository Evaluation of the FOCUS-CCTRN Trial

  Frontiers in Cardiovascular Medicine · 2021-09-03 · 1 citations

  articleOpen accessSenior authorCorresponding

  Cell therapy trials for heart failure (HF) have shown modest improvement; however, the mechanisms underlying improvement in some patients but not others are not well understood. Although immune cells are important in the course of HF, our understanding of the immune processes in HF is limited. The objective of this study was to evaluate associations between temporal changes in peripheral blood (PB) cell subpopulations and improved outcome in patients with chronic ischemic cardiomyopathy after bone marrow-derived mononuclear cell therapy or placebo in the FOCUS-CCTRN trial. Peripheral blood was collected at days 0, 1, 30, 90, and 180 from consented participants. We used flow cytometry to compare PB populations in patients with the best (cohort 1) or worst functional outcome (cohort 2) in three primary endpoints: left ventricular (LV) ejection fraction, LV end-systolic volume, and maximal oxygen consumption (VO 2 max). A linear mixed model was used to assess changes over time in 32 cell populations. The difference between each time point and baseline was calculated as linear contrast. Compared with cohort 2, patients who improved (cohort 1) had a higher frequency of CD45 + CD19 + B cells at days 0, 1, 90, and 180. CD11B + cells increased over baseline at day 1 in both cohorts and remained higher in cohort 2 until day 30. CD45 + CD133 + progenitor cells decreased over baseline at day 30 in cohort 1. We identified specific cell subpopulations associated with improved cardiac function in patients with chronic LV dysfunction. These findings may improve patient selection and prediction of outcomes in cell therapy trials.

  PublisherOA PDFDOI

• Cues from human atrial extracellular matrix enrich the atrial differentiation of human induced pluripotent stem cell-derived cardiomyocytes

  Biomaterials Science · 2021-01-01 · 16 citations

  articleOpen accessSenior authorCorresponding

  New robust and reproducible differentiation approaches are needed to generate induced pluripotent stem cell (iPSC)-derived cardiomyocytes of specific subtypes in predictable quantities for tissue-specific disease modeling, tissue engineering, and eventual clinical translation. Here, we assessed whether powdered decellularized extracellular matrix (dECM) particles contained chamber-specific cues that could direct the cardiac differentiation of human iPSCs toward an atrial phenotype. Human hearts were dissected and the left ventricle (LV) and left atria (LA) were isolated, minced, and decellularized using an adapted submersion decellularization technique to generate chamber-specific powdered dECM. Comparative proteomic analyses showed chamber-specific dECM segregation, with atrial- and ventricle-specific proteins uniquely present in powdered dECM-hA and dECM-hV, respectively. Cell populations differentiated in the presence of dECM-hA showed upregulated atrial molecular markers and a two-fold increase in the number of atrial-like cells as compared with cells differentiated with dECM-hV or no dECM (control). Finally, electrophysiological data showed an increase in action potentials characteristic of atrial-like cells in the dECM-hA group. These findings support the hypothesis that dECM powder derived from human atria retained endogenous cues to drive cardiac differentiation toward an atrial fate.

  PublisherOA PDFDOI

Recent grants

• NIH Grant U01HL100407

  NIH · $7.8M · 2017

• NIH Grant R01HL108627

  NIH · $3.0M · 2016

• NIH Grant R01HL057988

  NIH · $539k · 2002

• NIH Grant R01HL063346

  NIH · $2.7M · 2010

• NIH Grant R01HL063703

  NIH · $1.4M · 2005

Frequent coauthors

• Jay H. Traverse

  Abbott Northwestern Hospital

  254 shared

• Timothy D. Henry

  Pfizer (United States)

  239 shared

• Carl J. Pepine

  University of Florida

  234 shared

• Roberto Bolli

  University of Louisville

  192 shared

• Robert D. Simari

  University of Kansas

  175 shared

• Joshua M. Hare

  University of Miami

  173 shared

• Ray F. Ebert

  133 shared

• James T. Willerson

  121 shared

Labs

• Minnesota Center for Philosophy of SciencePI